249
Participants
Start Date
September 7, 2024
Primary Completion Date
January 30, 2026
Study Completion Date
June 30, 2026
Albendazole
Albendazole, 5-(prophylthio)-2-benzimidazole carbamate, is a broad-spectrum benzimidazole antihelminthic drug. It is provided as a white to off-white, circular, film-coated tablet with a slightly raised pentagonal projection on either side. This trial will use the 400 mg tablet formulation.
Oxfendazole
The active pharmaceutical ingredient is methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, which is a broad-spectrum benzimidazole antihelminthic. Oxfendazole is the sulphoxide metabolite of fenbendazole.
RECRUITING
Policlinico Asociacion Benefica Prisma, Santa Clara de Nanay
Policlinico Asociacion Benefica PRISMA-Laboratorio Satelite IQTLAB
UNKNOWN
National Institutes of Health (NIH)
NIH
University of Iowa
OTHER
University of Virginia
OTHER
Asociacion Benefica Prisma
OTHER